NCT04848064View on ClinicalTrials.gov

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

October 30, 2025

Study Completion Date

January 30, 2026

Conditions

Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

BIOLOGICAL

Mogamulizumab

Given IV

BIOLOGICAL

Natural Killer Cell Therapy

Given via infusion

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

John Reneau

OTHER